Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy
Source abstract
Abstract
Cancer immunotherapy, such as cancer vaccines and checkpoint blockades, has emerged as a promising cancer therapy in battling cancer, and revolutionized the field of cancer therapy. However, due to the low immune response, the clinical applications of immunotherapy have been greatly limited. As a classical category of anti-cancer drugs, metal and their complexes-based nanomedicine have already been extensively studied, and investigated as potential tools to enhance the anti-tumor immune response, in which they can reverse the immunosuppression without inducing toxicity or side effects. In this review, we summarize the-state-of-art metallic nanomedicine to enhance the efficacy of cancer immunotherapy. In the end, the obstacles and remaining challenges for metal-based nanomedicine are also summarized.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules10.1038/nm.2554 ↗
2. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer10.1056/NEJMoa1200690 ↗
3. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells
4. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors10.1126/science.aan3706 ↗
5. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
6. Immunotherapy and chemotherapy — a practical partnership10.1038/nrc1613 ↗
7. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial10.1016/S0140-6736(10)61381-5 ↗
8. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies10.1038/s41573-018-0007-y ↗
9. Medicinal inorganic chemistry: introduction10.1021/cr980419w ↗
10. Metals in medicine10.1002/(SICI)1521-3773(19990601)38:11<1512::AID-ANIE1512>3.0.CO;2-Y ↗
11. Challenges for molecular magnetic resonance imaging10.1021/cr100025t ↗
12. (99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer10.1016/j.eururo.2018.03.013 ↗
13. The bactericidal effect of silver nanoparticles10.1088/0957-4484/16/10/059 ↗
14. Breaking the intracellular redox balance with diselenium nanoparticles for maximizing chemotherapy efficacy on patient-derived xenograft models10.1021/acsnano.0c06190 ↗
15. Restoration of the immunogenicity of tumor cells for enhanced cancer therapy via nanoparticle-mediated copper chaperone inhibition
16. Platinum derivatives effects on anticancer immune response10.3390/biom10010013 ↗
17. Abplatin((IV)) inhibited tumor growth on a patient derived cancer model of hepatocellular carcinoma and its comparative multi-omics study with cisplatin10.1186/s12951-022-01465-y ↗
18. Disruption of dual homeostasis by a metal-organic framework nanoreactor for ferroptosis-based immunotherapy of tumor10.1016/j.biomaterials.2022.121502 ↗
19. Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy10.1021/jacs.1c09753 ↗
20. Combination of metal-phenolic network-based immunoactive nanoparticles and bipolar irreversible electroporation for effective cancer immunotherapy
21. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency10.1038/nature10246 ↗
22. T cell stemness and dysfunction in tumors are triggered by a common mechanism10.1126/science.aau0135 ↗
23. Calcium signaling in immune cells10.1038/ni.f.220 ↗
24. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses10.1016/j.immuni.2018.03.017 ↗
25. DNA-induced liquid phase condensation of cGAS activates innate immune signaling10.1126/science.aat1022 ↗
26. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
27. Zinc, aging, and immunosenescence: an overview
28. Metal drugs and the anticancer immune response10.1021/acs.chemrev.8b00396 ↗
29. Anticancer metal drugs and immunogenic cell death10.1016/j.jinorgbio.2016.06.021 ↗
30. Near-infrared II phototherapy induces deep tissue immunogenic cell death and potentiates cancer immunotherapy10.1021/acsnano.9b06040 ↗
31. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
32. A negatively charged Pt(iv) prodrug for electrostatic complexation with polymers to overcome cisplatin resistance10.1039/C9TB00155G ↗
33. Recent progress in polymer-based platinum drug delivery systems10.1016/j.progpolymsci.2018.07.004 ↗
34. Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance10.1016/j.msec.2018.10.092 ↗
35. Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II)10.1016/j.biomaterials.2011.06.072 ↗
36. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance10.1038/s41551-021-00728-7 ↗
37. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy10.1038/nnano.2011.149 ↗
38. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles10.1038/nm.2198 ↗
39. Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity10.1016/j.nano.2010.03.001 ↗
40. A cisplatin-loaded immunochemotherapeutic nanohybrid bearing immune checkpoint inhibitors for enhanced cervical cancer therapy10.1002/anie.201800422 ↗
41. A systematic strategy of combinational blow for overcoming cascade drug resistance via NIR-light-triggered hyperthermia10.1002/adma.202100599 ↗
42. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression10.1038/s41467-017-01651-9 ↗
43. Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade
44. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses
45. Gold nanoparticle reprograms pancreatic tumor microenvironment and inhibits tumor growth10.1021/acsnano.6b02231 ↗
46. Photothermal-activatable Fe3O4 superparticle nanodrug carriers with PD-L1 immune checkpoint blockade for anti-metastatic cancer immunotherapy10.1021/acsami.8b05876 ↗
47. Nanoparticle-induced exosomes target antigen-presenting cells to initiate Th1-type immune activation10.1002/smll.201200381 ↗
48. Combined magnetic hyperthermia and immune therapy for primary and metastatic tumor treatments10.1021/acsnano.9b08550 ↗
49. Surface-functionalized modified copper sulfide nanoparticles enhance checkpoint blockade tumor immunotherapy by photothermal therapy and antigen capturing10.1021/acsami.9b01107 ↗
50. Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
51. Immunostimulatory effect of chitosan conjugated green copper oxide nanoparticles in tumor immunotherapy10.1016/j.cyto.2019.154958 ↗
52. AIEgen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation10.1126/sciadv.abb2712 ↗
53. Tumor targeting via EPR: strategies to enhance patient responses10.1016/j.addr.2018.07.007 ↗
54. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
55. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
56. Cancer nanomedicines: so many papers and so few drugs10.1016/j.addr.2012.09.038 ↗
57. The entry of nanoparticles into solid tumours10.1038/s41563-019-0566-2 ↗
58. A nanoparticle's pathway into tumours10.1038/s41563-020-0669-9 ↗
59. Cancer nanomedicine for combination cancer immunotherapy10.1038/s41578-019-0108-1 ↗
60. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
61. Integration of nanoassembly functions for an effective delivery cascade for cancer drugs10.1002/adma.201401554 ↗
62. Inorganic nanocarriers for platinum drug delivery, Mater
63. Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy10.1016/j.jconrel.2012.06.004 ↗
64. Protein and mRNA Delivery Enabled by Cholesteryl-Based Biodegradable Lipidoid Nanoparticles10.1002/ange.202004994 ↗
65. Biodegradable hybrid stomatocyte nanomotors for drug delivery10.1021/acsnano.6b08079 ↗
66. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
67. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer10.1056/NEJMoa1200694 ↗
68. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase10.1038/nm934 ↗
69. Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy10.1039/D0NR04213G ↗
70. Multifunctional metal-organic framework-based nanoreactor for starvation/oxidation improved indoleamine 2,3-dioxygenase-blockade tumor immunotherapy10.1038/s41467-022-30436-y ↗
71. Toward biomaterials for enhancing immune checkpoint blockade therapy10.1002/adfm.201802540 ↗
72. Smart nanoreactors for pH-responsive tumor homing, mitochondria-targeting, and enhanced photodynamic-immunotherapy of cancer10.1021/acs.nanolett.8b00040 ↗
73. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death
74. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
75. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer10.1021/acsnano.7b00715 ↗
76. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy10.1002/adma.201802228 ↗
77. Platinum compounds: a new class of potent antitumour agents10.1038/222385a0 ↗
78. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals10.1016/j.canlet.2016.01.017 ↗
79. Consensus guidelines for the detection of immunogenic cell death10.4161/21624011.2014.955691 ↗
80. Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase10.1016/j.ejmech.2019.02.063 ↗
81. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents10.1002/anie.201402879 ↗
82. Induction of immunogenic cell death by chemotherapeutic platinum complexes10.1002/anie.201500934 ↗
83. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics10.1158/1078-0432.CCR-13-3141 ↗
84. Cisplatin in cancer therapy: molecular mechanisms of action10.1016/j.ejphar.2014.07.025 ↗
85. Immunogenic death of colon cancer cells treated with oxaliplatin10.1038/onc.2009.356 ↗
86. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress10.1038/onc.2010.500 ↗
87. Mouse models in oncoimmunology10.1038/nrc.2016.91 ↗
88. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
89. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models10.1080/2162402X.2020.1721810 ↗
90. Nanoenabled reversal of Ido1-mediated immunosuppression synergizes with immunogenic chemotherapy for improved cancer therapy10.1021/acs.nanolett.9b01807 ↗
91. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer10.1200/JCO.2000.18.16.2938 ↗
92. Oxaliplatin: a review in the era of molecularly targeted therapy10.3747/co.v18i1.708 ↗
93. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study10.1200/JCO.2005.03.0106 ↗
94. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer10.1056/NEJMoa032709 ↗
95. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis10.1021/acsnano.0c01676 ↗
96. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/anie.201804882 ↗
97. Chemodynamic therapy: tumour microenvironment-mediated Fenton and fenton-like reactions10.1002/anie.201805664 ↗
98. Tumor microenvironment-triggered aggregated magnetic nanoparticles for reinforced image-guided immunogenic chemotherapy10.1002/advs.201802134 ↗
99. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy10.1016/j.immuni.2015.11.024 ↗
100. Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer10.3390/cancers12030666 ↗